Prognosis after heart transplant in patients with hypertrophic and restrictive cardiomyopathy. A nationwide registry analysis.
Rev Esp Cardiol (Engl Ed)
; 77(4): 304-313, 2024 Apr.
Article
em En, Es
| MEDLINE
| ID: mdl-37984703
ABSTRACT
INTRODUCTION AND OBJECTIVES:
Posttransplant outcomes among recipients with a diagnosis of hypertrophic cardiomyopathy (HCM) or restrictive cardiomyopathy (RCM) remain controversial.METHODS:
Retrospective analysis of a nationwide registry of first-time recipients undergoing isolated heart transplant between 1984 and 2021. One-year and 5-year mortality in recipients with HCM and RCM were compared with those with dilated cardiomyopathy (DCM).RESULTS:
We included 3703 patients (3112 DCM; 331 HCM; 260 RCM) with a median follow-up of 5.0 [3.1-5.0] years. Compared with DCM, the adjusted 1-year mortality risk was HCM HR, 1.38; 95%CI, 1.07-1.78; P=.01, RCM HR, 1.48; 95%CI, 1.14-1.93; P=.003. The adjusted 5-year mortality risk was HCM HR, 1.17; 95%CI, 0.93-1.47; P=.18; RCM HR, 1.52; 95%CI, 1.22-1.89; P<.001. Over the last 20 years, the RCM group showed significant improvement in 1-year survival (adjusted R2=0.95) and 5-year survival (R2=0.88); the HCM group showed enhanced the 5-year survival (R2=0.59), but the 1-year survival remained stable (R2=0.16).CONCLUSIONS:
Both RCM and HCM were linked to a less favorable early posttransplant prognosis compared with DCM. However, at the 5-year mark, this unfavorable difference was evident only for RCM. Notably, a substantial temporal enhancement in both early and late mortality was observed for RCM, while for HCM, this improvement was mainly evident in late mortality.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Cardiomiopatia Hipertrófica
/
Cardiomiopatia Restritiva
/
Cardiomiopatia Dilatada
/
Transplante de Coração
Limite:
Humans
Idioma:
En
/
Es
Ano de publicação:
2024
Tipo de documento:
Article